Thomas van Dyke

Dr. Van Dyke is the principal investigator on the Grant and will oversee the

Research both at Forsyth and at the sub-recipient institution,

Brigham and Women's Hospital. He will be responsible for sharing data and

results within this collaborative project and via manuscript submission and

publication in peer-reviewed journals.

III. Description of How the FCOI Relates to the Research under the Grant Referenced Above and Basis for Determining that the FCOI Conflicts with such Research:

The Research under the Grant seeks to identify key control mechanisms for new

bone formation induced by the natural mediator, RvE1 and determine the

mechanism of action at the molecular, cellular and whole body level.

Dr. Van Dyke is a scientific founder of Resolvyx, a private company that is

focused on developing resolvins therapeutics for inflammatory diseases.

He retains a very small percentage of founder’s equity in Resolvyx.

Although Resolvyx may not presently have any interest in

pursuing the development of resolvin therapeutics for periodontal

disease, research demonstrating the potential of resolvins‐based

therapies, even in other disease areas, may further validate the

therapeutic potential of resolvins, and thus benefit Resolvyx. Given that

Dr. Van Dyke has has a financial interest in the company, it has been

determined that the financial interest creates a financial conflict of interest (FCOI)

which can be managed with the measures outlined below.